Linear IgA bullous dermatosis: A review

被引:16
|
作者
Ingen-Housz-Oro, S. [1 ]
机构
[1] Hop Henri Mondor, Serv Dermatol, F-94000 Creteil, France
来源
关键词
Linear IgA bullous dermatosis; Treatment; PEMPHIGOID ANTIGEN; NC16A DOMAIN; DISEASE; CHILDHOOD; AUTOANTIBODIES; ADULTS; PATIENT; ERYTHROMYCIN; ASSOCIATION; ANTIBODIES;
D O I
10.1016/j.annder.2011.01.010
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background. - Linear IgA bullous dermatosis (LABD) is a rare auto-immune bullous disease occurring in adults or childhood. Objective. - Review of literature about physiopathology, triggering factors, clinical data and treatment of LABD. Methods. - Research on Medline and Embase database without any time limit until April 2010. Because of the lack of randomized therapeutic trials in LABD, retrospective series and case reports have been analyzed. Results. - LABD is due to IgA auto-antibodies typically directed against a proteolytic fragment of BP180 antigen, a 97 or 120 kD protein, and/or other components of dermal-epidermal junction. The disease may be either idiopathic or triggered by several medication, most often vancomycin, but also other antibiotics, non-steroid anti-inflammatory, anti-hypertensive and anti-epileptic drugs... Clinically, eruption is typical in childhood with cluster and herpetiform arrangement of blisters and involvement of evocative anatomical sites. In adults, eruption is polymorphic, very atypical presentations are described. Diagnosis is confirmed by direct immunofluorescence which shows linear IgA deposition on the basement membrane zone. Immunoblot and immunoelectron microscopy are evocative in case of diagnosis hesitation. LABD may be associated with some inflammatory bowel disorders. There is no increased risk of cancer or Lymphoma. For drug-induced LABD, withdrawal of the medication is followed by a quick healing of the lesions. Dapsone is quickly efficient in idiopathic LABD. Colchicine, sulfapyridine and systemic corticosteroids are used in case of intolerance or inefficiency of dapsone. Some authors emphasize the efficiency of first-intent antibiotics in LABD of childhood. Conclusion. - A triggering drug should be always suspected and stopped. Dapsone is the reference treatment in idiopathic cases of LABD. (C) 2011 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:214 / 220
页数:7
相关论文
共 50 条
  • [11] IMMUNOPATHOLOGY OF LINEAR IGA BULLOUS DERMATOSIS
    BHOGAL, BS
    WOJNAROWSKA, F
    BLACK, MM
    DAS, AK
    MCKEE, PH
    JOURNAL OF CUTANEOUS PATHOLOGY, 1988, 15 (05) : 298 - 298
  • [12] Linear IgA bullous dermatosis in a neonate
    Lee, SYR
    Leung, CY
    Leung, CW
    Chow, CB
    Leung, KM
    Lee, QU
    ARCHIVES OF DISEASE IN CHILDHOOD-FETAL AND NEONATAL EDITION, 2004, 89 (03): : F280 - F280
  • [13] Linear IgA bullous dermatosis of children
    Pierchalla, A.
    Bruch-Gerharz, D.
    Homey, B.
    Reifenberger, J.
    HAUTARZT, 2011, 62 (04): : 262 - 264
  • [14] PHOTOAGGRAVATED IGA LINEAR BULLOUS DERMATOSIS
    BRULEY, C
    GAUCHY, O
    BELTZERGARELLY, E
    BINET, O
    ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE, 1987, 114 (11): : 1358 - 1359
  • [15] A CASE OF LINEAR IGA BULLOUS DERMATOSIS
    Grizzle, K. B.
    Hofto, M.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2016, 64 (02) : 587 - 587
  • [16] LINEAR IGA BULLOUS DERMATOSIS IN A NEONATE
    HRUZA, LL
    MALLORY, SB
    FITZGIBBONS, J
    MALLORY, GB
    PEDIATRIC DERMATOLOGY, 1993, 10 (02) : 171 - 176
  • [17] VANCOMYCIN AND LINEAR IGA BULLOUS DERMATOSIS
    Ismail, A.
    Quezada, R. E. Gavidia
    Iwuji, K.
    Tarbox, M.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2018, 66 (02) : 461 - 462
  • [18] Linear IgA bullous dermatosis mimicking a neutrophilic dermatosis
    Dietrich, Nathalie
    Beltraminelli, Helmut
    Borradori, Luca
    EUROPEAN JOURNAL OF DERMATOLOGY, 2012, 22 (05) : 713 - 714
  • [19] Symblepharon in Linear IgA Bullous Dermatosis
    Tsui, Jonathan C.
    Onishi, Spencer
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (13): : 1219 - 1219
  • [20] Linear IgA Bullous Dermatosis of Childhood
    Pandya, Arjun
    Horissian, Mikael
    NEW ENGLAND JOURNAL OF MEDICINE, 2025, 392 (11): : 1120 - 1120